Iridium Corporation (IRMD)
iRadimed Q2 Earnings Call Highlights
iRadimed NASDAQ: IRMD reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp.
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript
iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.
IRADIMED CORPORATION (IRMD) Q3 2025 Earnings Call Transcript
IRADIMED CORPORATION ( IRMD ) Q3 2025 Earnings Call November 3, 2025 11:00 AM EST Company Participants Roger Susi - Founder, Chairman, CEO & President John Glenn - CFO & Corporate Secretary Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Kyle Bauser - ROTH Capital Partners, LLC, Research Division Presentation Operator Welcome to the IRADIMED CORPORATION Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded today, November 3, 2025, and contains time-sensitive accurate information that is valid only for today.
IRadimed: Continued Value Unlock With Extensive Reinvestment Runway
IRadimed Corporation demonstrates exceptional economic characteristics, with high NOPAT margins, robust free cash flow, and consistent value creation for shareholders. Management has effectively reinvested capital, generating over $18 in market value for every $1 invested since FY'22, and consistently exceeding a 12% ROIC hurdle rate. Despite modest sales growth, IRMD's profitability and cash conversion remain strong, with a persistent ability to redeploy earnings at attractive returns.
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2025 Earnings Conference Call August 1, 2025 11:00 AM ET Company Participants John F. Glenn - CFO & Corporate Secretary Roger E.
iRadimed (IRMD) Q2 Earnings and Revenues Surpass Estimates
iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.
New Strong Sell Stocks for June 12th
LYB, IRMD and SONY have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2025.
IRADIMED CORPORATION (IRMD) Q1 2025 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2025 Earnings Conference Call May 5, 2025 9:00 AM ET Company Participants Roger Susi - Founder, President & CEO John Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Welcome to the IRADIMED Corporation First Quarter of 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
IRadimed (IRMD) Lags Q1 Earnings Estimates
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.36 per share a year ago.
